Inventiva (NASDAQ:IVA) Earns Sell (D-) Rating from Weiss Ratings

Inventiva (NASDAQ:IVA)‘s stock had its “sell (d-)” rating reissued by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

IVA has been the subject of a number of other reports. Piper Sandler assumed coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price objective for the company. HC Wainwright assumed coverage on shares of Inventiva in a research note on Wednesday, September 3rd. They issued a “buy” rating and a $20.00 price objective for the company. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price objective on shares of Inventiva in a research note on Tuesday, September 30th. Finally, Guggenheim boosted their price objective on shares of Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.57.

Inventiva Stock Performance

Shares of Inventiva stock opened at $5.36 on Wednesday. The firm has a fifty day simple moving average of $5.05 and a 200-day simple moving average of $3.90. Inventiva has a 1-year low of $1.60 and a 1-year high of $6.55.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Creative Planning bought a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.